Table 1.
Comparison of the sociodemographic and metabolic parameters according to the body weight categories in patients with type 2 diabetes
| Total patients (n = 4,648) |
Normal (n = 468) (10.1%) |
Overweight (n = 1,439) (31.0%) |
Obesity (n = 2,225) (47.9%) |
Severe obesity (n = 516) (11.1%) |
p | |
|---|---|---|---|---|---|---|
| Age, years | 58.48 ± 10.45 | 59.17 ± 11.91 | 59.46 ± 10.59 | 58.19 ± 10.16 | 56.43 ± 9.52 | <0.001 |
| Female gender | 2,731 (58.8) | 185 (39.5) | 635 (44.1) | 1,459 (65.6) | 452 (87.6) | <0.001 |
| HbAlc, % | 7.73 ± 1.74 | 7.67 ± 1.83 | 7.60 ± 1.72 | 7.80 ± 1.71 | 7.89 ± 1.78 | 0.001 |
| HbAlc, mmol/mol | 61.0 ± 16.67 | 60.03 ± 17.65 | 59.06 ± 16.45 | 61.7 ± 16.34 | 62.7 ± 17.1 | 0.001 |
| DM duration, years | 10.84 ± 7.53 | 11.20 ± 8.17 | 10.68 ± 7.70 | 10.82 ± 7.35 | 11.08 ± 7.23 | 0.513 |
| Exercise | 896 (19.6) | 120 (26.0) | 342 (24.1) | 370 (16.9) | 64 (12.5) | <0.001 |
| Smoking | 588 (12.7) | 86 (18.4) | 208 (14.5) | 243 (11.0) | 51 (9.9) | <0.001 |
| Higher education | 1,765 (38.5) | 264 (56.8) | 690 (48.5) | 699 (31.9) | 112 (21.9) | <0.001 |
| LDL-C, mg/dL | 113.92 ± 36.17 | 117.69 ± 37.92 | 113.64 ± 36.22 | 114.10 ± 35.75 | 110.38 ± 35.90 | 0.021 |
| HDL-C, mg/dL | 46.58 ± 12.93 | 50.31 ± 15.86 | 46.47 ± 13.10 | 46.00 ± 12.28 | 45.87 ± 11.58 | <0.001 |
| TG, mg/dL | 181.75 ± 128.47 | 144.65 ± 98.41 | 177.69 ± 138.28 | 191.90 ± 130.01 | 183.38 ± 110.09 | <0.001 |
| eGFR, mL/min | 87.45 ± 30.05 | 87.07 ± 45.39 | 86.66 ± 29.96 | 87.48 ± 25.98 | 89.70 ± 29.54 | 0.380 |
| Microvascular complications | 2,209 (47.5) | 179 (38.2) | 636 (44.2) | 1,101 (49.5) | 293 (56.8) | 0.001 |
| Macrovascular complications | 1,123 (24.2) | 103 (22.0) | 360 (25.0) | 544 (24.4) | 116 (22.5) | 0.256 |
| Home ABP <135/85 mm Hg | 3,219 (69.8) | 368 (79.8) | 1,056 (73.7) | 1,471 (66.7) | 324 (63.3) | <0.001 |
| LDL-C, mg/dL | 1,644 (37.3) | 158 (34.6) | 519 (38.0) | 765 (36.5) | 202 (41.2) | 0.140 |
| HbA1c <7% (53 mmol/mol) | 1,820 (40.1) | 194 (42.1) | 629 (45.0) | 817 (37.5) | 180 (35.9) | <0.001 |
| Triple target | 472 (10.4) | 56 (12.1) | 173(12.3) | 196 (9.0) | 48 (9.4) | 0.009 |
| Insulin treatment | 2,147 (46.2) | 197 (42.1) | 606 (42.1) | 1,081 (48.6) | 263 (51.0) | <0.001 |
| OAD treatment | 4,126 (88.8) | 404 (86.3) | 1,267 (88.0) | 1,988 (89.3) | 467 (90.5) | 0.118 |
| OADs, n | 1.51 ± 0.92 | 1.43 ± 0.92 | 1.52 ± 0.93 | 1.53 ± 0.92 | 1.45 ± 0.83 | 0.060 |
| Anti-HT treatment | 2,754 (59.3) | 214 (45.7) | 797 (55.4) | 1,388 (62.4) | 355 (68.8) | <0.001 |
| Anti-HT drugs, n | 1.74 ± 0.85 | 1.54 ± 0.76 | 1.67 ± 0.81 | 1.77 ± 0.87 | 1.88 ± 0.87 | <0.001 |
| Statin treatment | 1,836 (39.5) | 158 (33.8) | 566 (39.3) | 907 (40.8) | 205 (39.7) | 0.047 |
Data are presented as n (%) or mean ± SD. Bold p values are significant. HbA1c, glycated hemoglobin; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; eGFR, estimated glomerular filtration rate; ABP, arterial blood pressure; OAD, oral antidiabetic drugs; HT, hypertension.